|Table of Contents|

Preparation of Personalized Colorectal Cancer Tumor Vaccine(PDF)

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

Issue:
2022年01期
Page:
74-80
Research Field:
·生物学·
Publishing date:

Info

Title:
Preparation of Personalized Colorectal Cancer Tumor Vaccine
Author(s):
Sheng Hui; Zhao Zhihui
(School of Life sciences,Nanjing Normal University,Institute of Biochemistry and Biological Products,
Keywords:
colorectal cancer; tumor vaccine; bioorthogonal reaction; dendritic cells
PACS:
R735.3+7
DOI:
10.3969/j.issn.1001-4616.2022.01.011
Abstract:
At present,due to the difficulty of identifying tumor-specific antigens and the inability to deliver broad-spectrum tumor antigens to antigen-presenting cells through the activating endocytic receptor pathway,the clinical therapeutic effect of existing tumor vaccines is not good.Meanwhile,the tumor cell antigens with highly sialylated modification can lead to immune tolerance. Therefore,this study tried to use metabolic incorporation to label the sialic acid of the tumor antigen with an orthogonal group-azide(-N3),and at the same time label the ligand of a specific activating phagocytic receptor with another orthogonal group-Alkynes,through bio-orthogonal reactions to prepare tumor vaccines. Firstly,construct and express the recombinant protein mlgG1Fc that can target dendritic cells(DCs),and then modify the ligands of the phagocytic receptor with compounds containing orthogonal groups. Secondly,the azide-modified unnatural sugars are used to label the glycosylation modification sites of CT26.WT colon cancer cell antigen through metabolic incorporation to prepare N3-TAg. Finally,the phagocytic receptor ligand is conjugated with a broad-spectrum tumor antigen through a copper-free click reaction to obtain a colorectal cancer tumor vaccine. The results proved that the use of genetic engineering methods to successfully express the mlgG1Fc protein,and obtain the DIBO-modified mlgG1Fc protein,and conjugate mlgG1Fc-DIBO with N3-TAg to prepare a targeted and stable colorectal cancer tumor vaccine. The research has laid the foundation for the preparation of new tumor vaccines in methodology.

References:

[1] CHEN W,SUN K,ZHENG R,et al. Cancer incidence and mortality in China,2014[J]. Chinese journal of cancer research,2018,30(1):1-12.
[2]孙燕,顾晋,汪建平. 中国结直肠癌诊疗规范(2017 年版)[J]. 上海医学,2018,41(8):449-463.
[3]薛婷,冯峰. 结直肠癌能谱CT的研究进展[J]. CT理论与应用研究,2020,29(6):751-758.
[4]ZHANG Y,QIN B L. The research progress of CAR-T cell therapy in the colorectal cancer[J]. Modern oncology,2019,27(1):157-161.
[5]CHEN W,ZHENG R,BAADE P D,et al. Cancer statistics in China,2015[J]. CA:A cancer journal of clinicicans,2016,66(2):115-132.
[6]ZHAO J,CHEN Y,DING Z Y,et al. Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment[J]. Front pharmacol,2019,10:1184.
[7]CHRISTOFI T,BARITAKI S,FALZONE L,et al. Current perspectives in cancer immunotherapy[J]. Cancers(basel),2019,11(10):1472.
[8]HE Q,GAO H,WANG J Z. Chinese journal of new drugs[J]. Nature reviews immunology,2020,29(21):2401-2409.
[9]SOLINAS C,AIELLO M,MIGLIORI E,et al. Breast cancer vaccines:heeding the lessons of the past to guide a path forward[J]. Cancer treat rev,2020,84:101947.
[10]HE Q,GAO H,GAO M,et al. Anti-gastrins antiserum combined with lowered dosage cytotoxic drugs to inhibit the growth of human gastric cancer SGC7901 cells in nude mice[J]. Cancer,2015,6(5):448-456.
[11]HE Q,GAO H,GAO M,et al. Immunogenicity and safety of a novel tetanus toxoid-conjugated anti-gastrin vaccine in BALB/c mice[J]. Vaccine,2018,36(6):847-852.
[12]ZHOU Q P. Current status of tumor neoantigen vaccine research[J]. Biological chemical engineering,2020,6(5):154-156.
[13]许若琳,史曼. 树突状细胞与肿瘤免疫[J]. 科学技术创新,2019,35:28-29.
[14]RACHEL L S,SREEKUMAR B,NINA B. Dendritic cell-based immunotherapy[J]. Cell research,2017,27:74-95.
[15]IVAN E,COLOVAI A I. Human Fc receptors:critical targets in the treatment of autoimmune diseases and transplant rejections[J]. Human immunology,2006,67(7):479-491.
[16]祁培培,曹洁. 人免疫球蛋白G Fcγ 受体的细胞分布及其功能研究进展[J]. 细胞与分子免疫学杂志,2012,28(5):557-559.
[17]QIAN J,ZHANG X W,DING J. The effect of sialyltransferases on the sialylated structures in cancer[J]. Chinese bulletin of life sciences,2006,18(3):227-231.
[18]ZHOU X M,YANG G L,GUAN F. Biological functions and analytical strategies of sialic acids in tumor[J]. Cells,2020,9(273):1-17.
[19]陈红梅,张建华,徐仑. KL-6与呼吸系统疾病[J]. 国际儿科学杂志,2008(2):137-139.
[20]LUCHANSKY S J,BERTOZZI C R. Azido sialic acids can modulate cell-surface interactions[J]. Chembiochem:a European journal of chemical biology,2004,5:1706-1709.
[21]KEPPLER O T,HORSTKORTE R,PAWLITA M,et al. Biochemical engineering of the N-acyl side chain of sialic acid:biological implications[J]. Glycobiology,2001,11:11R-18R.
[22]SAXON E,BERTOZZI C R. Cell surface engineering by a modified Staudinger reaction[J]. Science,2000,287:2007-2010.
[23]SONG Y L,ZHU Y Y,ZHOU Y,et al. IFN-γ and tumor immunity[J]. Modern oncology,2021,29(1):0143-0148.
[24]THOMAS S,PRENDERGAST G C. Cancer vaccines:a brief overview[J]. Methods in molecular biology,2016,1403:755-761.
[25]SABADO R L,BALAN S,BHARDWAJ N. Dendritic cell-based immunotherapy[J]. Cell research,2017,27(1):74-95.
[26]黎华丽,郑勇斌. 结直肠癌免疫治疗的研究进展[J]. 山东医药,2019,59(19):90-92.
[27]吴龙龙,宋红丽. 肝脏耐受性树突状细胞与肝移植免疫研究进展[J]. 中华肝胆外科杂志,2021,27(2):149-152.
[28]CHEN J,QIAO Y D,LI X,et al. Intratumoral CD45+CD71+erythroid cells induce immune tolerance and predict tumor recurrence in hepatocellular carcinoma[J]. Cancer letters,2021,499:85-98.
[29]宋政文,赵智辉. 靶向树突状细胞的结肠癌肿瘤疫苗的制备[J]. 南京师大学报(自然科学版),2020,43(3):112-119.

Memo

Memo:
-
Last Update: 1900-01-01